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INTRODUCTION 
 INTRODUCTION 
 
 Use of tobacco products, including cigarettes, cigars, pipes and snuff is 
associated with high mortality and morbidity. Cigarette smoking is now 
responsible for more than one million premature deaths each year. Main 
stream cigarette smoke inhaled by the smoker is composed of a particular 
phase and a gas phase; tar is the total particulate phase without water or 
nicotine. There are 0.3 to 3.3 billion particles per milliliter of mainstream 
smoke and more than 4000 constituents, including 43 known carcinogens. In 
addition to these chemical carcinogens, cigarette smoke contains carcinogenic 
metals such as arsenic, nickel, cadmium and chromium; potential promoters 
such as acetaldehyde and phenol; irritants such as nitrogen dioxide and 
formaldehyde; cilia toxins such as hydrogen cyanide and carbon monoxide. 
 
Carbon monoxide is a colorless, odorless gas produced during 
incomplete combustion of tobacco. It has 200 times higher affinity for 
hemoglobin than oxygen does and impairs release of oxygen from 
hemoglobin. Thus carbon monoxide exposure decreases the delivery of 
oxygen to peripheral tissues. Carbon monoxide also binds to other hemi 
containing proteins, such as myoglobin and cytochrome oxidase. 
 
Nicotine is an important constituent of cigarette smoke. It is an 
alkaloid that readily crosses the blood brain barrier and stimulates nicotine 
receptors in the brain. It is also responsible for the acute pharmacologic 
effects associated with tobacco use that are most likely mediated by 
 catecholamines; increased heart rate increased contractility and cardiac output 
and mobilization of free fatty acids. Nicotine is responsible for tobacco 
addiction. 
 
Unburned cured tobacco contains nicotine, carcinogens and other 
toxins capable of causing gum disease and oral cancer. 
 
Cigarette smokers are increased risk of developing cardio vascular 
disease like large vessel atherosclerosis and coronary artery disease, 
myocardial ischemia, myocardial infarction, sudden death, systemic 
hypertension, cerebrovascular disease and stroke, subarachnoid haemorrhage. 
 
Peripheral vascular disease like thromboangitis obliterans (TAO) and 
arteriosclerosis obliterans are common in smoker. 
 
Gastric and duodenal ulcer disease is more prevalent in smokers. 
Smoking impairs ulcer healing, favors recurrence of ulcers, inhibits pancreatic 
HCO3 secretion and decreases the pressure of esophageal and pyloric 
sphincter.  
 
Various types of cancer are caused by chronic smoking. They are 
cancer of oral cavity, larynx, lung, esophagus, stomach, pancreas, kidney, 
urinary bladder, uterine cervix, myelocytic leukemia. 
 
 Male smokers have 4-25 times higher mortality secondary to COPD 
than non smoker. Prolonged cigarette smoking impairs ciliary function; 
inhibit function of alveolar macrophages and lead to hypertrophy and 
hyperplasia of mucus secreting glands. It increases airway resistance due to 
vagal nerve mediated smooth muscle constriction by way of stimulating 
submucosal irritant receptors.  
 
 Primary care physicians are in a unique position to monitor the 
respiratory health of the community. The inclusion of Spirometry as a routine 
test, especially in patients at risk of respiratory disease (e.g. Smokers), will 
lead to earlier detection of respiratory disease and more effective intervention 
and treatment. 
 
 Ninety percent of non-asthmatic patients with airflow obstruction have 
COPD. In addition, COPD is characterized by an accelerated decline in 
spirometric values. The disease progresses slowly and the early signs (e.g. 
Cough and sputum) are often ignored or are not significant enough to prompt 
the patient to seek treatment. Consequently, a diagnosis is often not made 
until about half of the lung's large reserve capacity is already lost causing 
significant symptoms. Because there is a close relationship between the risk 
of COPD and the intensity and duration of smoking, Spirometry is a very 
important test for the early detection of COPD in smokers and ex-smokers. 
When provided with evidence of airflow limitation, patients are more likely to 
cease smoking and this will reduce the rate of FEV1 decline and thus modifies 
the natural history of the disease. 
 
  Although there is the possibility that a finding of normal Spirometry in 
a smoker may reinforce their smoking habit, such findings can be used as 
'teachable moments' when the patient has increased awareness of the risks. 
 
Abnormalities in pulmonary function test are common in smokers. 
Spirometric analysis shows a restrictive or obstructive pattern in chronic 
smokers. 
 
Restrictive pattern is characterized by reduced total lung capacity and 
reduced vital capacity. Obstructive pattern is characterized by decreased 
FEV1/FVC ratio. Reduced mid expiratory flow rate (FEF25-75%) detects only 
small airway involvement. 
 
         Spirometry screening of smokers and ex-smokers has been shown to 
enhance early detection of COPD when treatment and intervention can have a 
positive effect on disease progression. Furthermore, the demonstration of 
airflow limitation to the patient has been shown to motivate smokers to quit. 
 
In this study, 150 chronic smokers and 50 non smokers who came to 
hospital for respiratory or non respiratory symptoms are evaluated for lung 
function test by spirometry and categorized according to GOLD criteria. 
 
  
 
 
 
 
AIM OF THE STUDY 
 AIM OF THE STUDY 
 
 Aim of the study is to find out prevalence of undetected 
pulmonary function abnormalities in chronic male 
smokers. 
 
  
 
 
 
 
 
REVIEW OF LITERATURE 
 REVIEW OF LITERATURE 
 
Smoking 
 Cigarette smoke is a heterogeneous aerosol produced by incomplete 
combustion of tobacco leaf. On an average, smokers lose more than one day 
of life every week. 
 
Main stream smoke:  
Smoke emerging from mouthpiece during puffing 
 
Side stream smoke:  
Smoke emitted between puffs at the burning cone and from the 
mouthpiece. Side stream smoke contains more of particulate matter especially 
carcinogens. 
 
Contents of Cigarette Smoke 
Carcinogens   
 Tar 
 Polynuclear aromatic hydrocarbons   
 Naphthylamine 
 N – nitrosonornicotine 
 Benzopyrene 
 Trace metals – nickel, arsenic. 
 Polonium 210 
 Nitrosamines, hydrazine, vinyl chloride 
 Co-carcinogens                                       
 Phenol, cresol, catechol . 
 
Tumor accelerator            
                       Indole, Carbazole     
 
Pharmacology of Cigarette Smoke 
 There are more than 4000 substances identified in cigarette smoke. 
They have antigenic, cytotoxic, mutagenic and carcinogenic properties. 
 
 Nicotine is a toxic alkaloid present in cigarette smoke, which is both a 
ganglionic stimulant and a depressant. 
 
Acute cardiovascular effects of nicotine1 
            Are increased in, 
 
a. both systolic and diastolic BP 
b. heart rate 
c. force of myocardial contraction and excitability 
d. myocardial oxygen consumption 
e. coronary artery blood flow 
f. Peripheral vasoconstriction. 
 
Major carcinogens found in cigarette smoke are polynuclear aromatic 
hydrocarbons, aromatic amines and nitrosamines. Co-carcinogens like 
catechols enhance the carcinogenicity. 
 Carbon monoxide is a toxic gas found in smoke (2-6%) and causes 
polycythemia and CNS impairment. This is the major cause for COPD. 
 
Smoking also causes chronic cough, sputum, dyspnoea, change in lung 
function tests, increase in incidence of pneumonia and inflammatory lung 
disease. 
 
Characteristics of Smokers 
Smokers drink more alcohol, coffee and tea than non smokers, 
Menopause comes earlier in smoking women. Smokers have impaired 
exercise performance, impaired immune system compared to nonsmokers. 
They show increase in hematocrit, WBC count and platelet count, there is 
decrease in leucocyte vitamin C levels, serum uric acid and albumin in 
smokers. The ratio of HDL to LDL cholesterol is also reduced. 
 
Clinical Correlations 
Common disorders associated with smoking include atherosclerotic 
cardiovascular disease, cancer and COPD. The risk is dependent on duration, 
intensity and type of smoke exposure. 
 
Smoking and Cardiovascular Disease 
Smoking, hypertension, and hypercholesterolemia are three major risk 
factors for coronary heart disease (CHD). Presence of two out of the three risk 
factors may produce a 4 fold increase in CHD risk and 3 risk factors produces 
a 8 fold increase in CHD risk. 
  CHD death rates are 60-70% greater in male smokers than in 
nonsmokers. 
 Sudden death is 2-4 times more common in young male 
smokers. 
 Women smokers also develop CHD especially when they take 
oral contraceptive pill also. 
 
Those who continue to smoke after acute MI are most likely to die 
from CHD than those who quit smoking. Smokers have increased 
perioperative mortality than nonsmokers. 
 
Similarly, cerebrovascular disease and stroke is also common in 
smokers. In women smokers, subarachnoid haemorrhage is more common; 
oral contraceptives increase the risk in them. 
 
Peripheral vascular disease like Thromboangitis obliterans (TAO) and 
arteriosclerosis obliterans are common in smokers. 
 
Hypertensives who smoke are at a greater risk of developing malignant 
hypertension and they die from complications of hypertension. 
 
Smoking and Cancer2 
Smoking causes cancer of  
Oral cavity Pancreas 
Larynx Kidney 
Lung Urinary bladder 
Esophagus Uterine cervix 
Stomach Myelocytic leukemia 
 Smoking Index (SI) 
 SI = number of cigarette/day x total duration in years. 
 SI <100             Mild smoker 
 SI 101 - 300      Moderate smoker 
 SI > 300            Heavy smoker  
Lung cancer is common if smoking index is more than 300. 
 
Pack Year 
 Number of pack years = number of packet of cigarette/day x number of 
years (one pack = 20 cigarettes.) The risk of developing lung cancer is 40 
times more in patients who smoke 2 packs per day for 20 years. 
 
Smoking and Respiratory Disease 
 Male smokers have 4-25 times higher mortality secondary to COPD 
than nonsmokers. 
 
 Prolonged cigarette smoking impairs ciliary movement, inhabits 
function of alveolar macrophages and leads to hypertrophy and hyperplasia of 
mucus secreting glands3. It also inhibits antiproteases and causes polymorphs 
to release proteolytic enzymes acutely. The inhaled cigarette smoke increase 
airway resistance due to vagally mediated smooth muscle constriction by way 
of stimulating submucosal irritant receptors. 
 
Abnormalities in pulmonary function tests, (measurements of elastic 
recoil, airflow in large and small airways and diffusing capacity) are common 
 in smokers4. There is increase in incidence of respiratory infections and 
deaths due to pneumonia and influenza. Postoperative respiratory 
complications, spontaneous pneumothorax are also common. Chronic 
pharyngitis, chronic laryngitis and chronic bronchitis occur more frequently in 
smokers. 
 
 Patients with airflow obstruction are at increased risk of developing 
post surgery complication such as pneumonia and atelectasis. Therefore, 
Spirometry is indicated in pre surgical check up before thoracic and upper 
abdominal surgery and in patients with history of smoking, cough, wheezing 
or pulmonary disease. Presence of mid obstruction carries a low risk but 
moderate to severe airway obstruction puts a patient in high risk category5. 
 
            22% of adult male population of India is smokers. Ideally all smokers 
above the age of 40 should get Spirometry done for early detection of 
emphysema in asymptomatic smokers6. 
 
Smoking and Gastrointestinal Disorders7 
 In smokers, there are changes in hard and soft tissues of the mouth, 
discoloration of the teeth and there is decreased sensation of taste and smell. 
 
 Gastric and duodenal ulcer disease is more prevalent in smokers both 
in males and females. Smoking impairs ulcer healing, favors recurrence of 
ulcers, inhibits pancreatic HCO3- secretion and decreases the pressure of 
esophageal and pyloric sphincters. Inhibition of nocturnal acid secretion by H2 
blockers is also prevented by smoking. 
 Smoking and Depression8 
 Prevalence of smoking is increased in those who have a major 
depressive disorder. 
 
Smoking and Body Weight 
 There is an inverse association between smoking and body weight. 
Weight gain occurs after cessation of smoking. 
 
Smoking and Pregnancy 
 Smoking delays conception and smoking during pregnancy affects the 
fetus. Babies born to mothers who smoke have a weight of about 170 gm less 
than the babies born to non-smokers. This is due to impaired uteroplacental 
circulation. 
 
 Spontaneous abortion, fetal death, neonatal death and sudden infant 
death syndromes are also common. The long term physical growth and 
intellectual development of the child is also affected. 
 
Passive Smoking 
Since side stream smoke is diluted in a large volume of air, smoke 
exposure from involuntary inhalation is less than that associated with 
smoking.  
 
Majority of housewives in rural areas of our country use smoky fuels 
for cooking such as firewood, dried dung, crop residues and agricultural 
wastes. A housewife spends around 6 hours a day in such an environment9 
 exposure to such pollution leads to restrictive and obstructive respiratory 
disease10. 
 
Vehicular pollution has been found to be an important cause of 
respiratory symptoms in people in metropolitan cities11. 
 
           Passive smoking is one of the causes for lung cancer in nonsmokers. 
Parental smoking is a cause for middle ear effusions, acute or chronic 
respiratory illness and asthma in children. Passive smoking may also cause 
coronary heart disease. 
 
Smoking and Drugs 
 Tobacco smoke constituents induce hepatic microsomal enzyme 
systems which are important in the metabolism of drugs like propranolol, 
theophylline and propoxyphene and hence increase in dose in smokers is 
recommended. 
 
Type of Smoking 
 Using low tar-nicotine cigarettes shows decrease in risk of developing 
lung and laryngeal cancers. The risk is the same for both high tar-nicotine 
cigarettes and low tar-nicotine cigarettes when the number of cigarettes 
smoked per day and the duration of smoking are more in the latter group. 
 
 Using pipe or cigar reduces the overall risk. ( the patients do not inhale 
more smoke since the alkaline pH of tobacco used in them is a potent irritant 
of respiratory tract.) 
 Death rates of cigar, pipe and cigarette smokers are more or less the 
same as far as carcinoma of oral cavity, larynx and esophagus are concerned.  
Chewing tobacco or using snuff produces increased risk for oral cancers. 
  
Cessation of smoking produces immediate and long-term physical, 
psychological and economic benefits. The sense of smell and taste may 
improve within a few days of quitting the cigarette. 
 
 One year after stopping, there is a decrease in risk for CHD; cessation 
also decreases risk for tobacco related cancers, cerebrovascular disease, MI 
and COPD. 
 
Cessation Process12 
 Smokers should stop smoking in a stepwise process. First they think 
about quitting, and then they should maintain an ex-smoker status. 
 
 Most successful quitters replace and recycle through these stages 3-4 
times before abstinence. Factors encouraging long-term cessation include 
decreased social acceptability, increased concern about health consequences 
and increased cost of tobacco. 
 
Cessation Methods 
 Counselling, group therapy, behavioural training, hypnosis, and 
acupuncture are the methods tried. 
 Pharmacotherapy13 
1. Nicotine containing chewing gum 2 or 4 mg chewed over 20-30 
minutes, repeated up to 60 mg/day. 
2. Transdermal nicotine patch; started as high does patch, 21 mg/day for 
6 weeks followed by intermediate does patch, 14 mg/day for 2-4 weeks 
followed by low does patch, 7 mg/day for 2-4 weeks. 
1. Nicotine nasal spray 2 sprays (equivalent to 1 mg) as needed not to 
exceed 5 doses /hr or 40 doses/ day. 
2. Nicotine inhaler, 6-16 cartridges/day for 12 weeks followed by 
tapering over 6-12 weeks. 
3. Bupropion hydrochloride. 
 
It acts by inhibiting neuronal reuptake of Dopamine and nor 
adrenaline. The drug is started 1 week before quitting smoking at a does of 
150mg orally OD for 3 days followed by 150mg orally BD for 7-12 weeks, 
increase smoking cessation rate when used with behaviour modification 
programme and can be combined with nicotine replacement. 
 
Contraindication for Pharmacotherapy 
 Seizure disorder 
 Eating disorder like bulimia or anorexia nervosa. 
 Administration of MAO inhibitors. 
 Head trauma 
 CNS tumor 
 Concomitant antidepressants or antipsychotics 
 Hypersensitivity 
 Concomitant alcohol or benzodiazepines should be avoided. 
 Spirometry and Measurement 
 
Definition 
 Spirometry is a test of lung function that measures how much and how 
quickly air can be moved into and out of the lungs. The measurements are 
made using a spirometer. 
 
 Spirometer 
 A spirometer is an instrument used to measure respired volumes and 
flows (i.e. Spirometry). Many spirometers are able to measure both 
Inspiratory and expiratory airflow. 
 
Pulmonary function tests are undertaken to find out whether the patient 
has lung disease. The results of the pulmonary function tests of a given 
individual are compared with those obtained from a normal population of 
comparable height, age and gender. The test is considered abnormal if it falls 
outside the range based on the standard error of the estimate in which 95% of 
normal lies14.  
 
Pulmonary functions may be impaired due to physiologic and anatomic 
abnormalities. They are evaluated by pulmonary function tests. American 
Thoracic Society has recommended including forced Spirometry 
measurements and testing of single breath diffusing capacity15 . 
 
 A recommended approach is to record maximal readings of forced 
expiratory volume in one second FEV1 and FVC whether or not they are from 
the same tracing 16,17. 
 
Peak of flow volume should be sharp. Peak expiratory flow rate 
(PEFR) is best non – invasive test of expiratory effort and should be 
proportional to FEV118. 
 
Spirometric parameters depend on weight, age, sex and race19. In India 
variations in values of Spirometry has been reported depending upon height, 
age, sex and socio economic status. Higher values have been reported in 
North Indians in comparison to Central India 20,21,22,23,24. 
 
Uses of Spirometry 
 Correctly performed Spirometry, using an accurate spirometer 
provides: 
• Rapid and objective assessment of airflow obstruction and 
restrictive conditions. 
• Differentiation between asthma and COPD. 
• Early detection and monitoring of disease progression (e.g. 
COPD). 
• Quantitative assessment of the severity of airflow obstruction. 
• Incorporate guideline recommendations for therapy based on 
COPD and asthma severity25,26.  
• Quantitative assessment of the response to therapy. 
 • Population screening and case finding to detect airflow 
obstruction – especially smokers and ex-smokers (with and 
without symptoms) and all patients with respiratory symptoms. 
• Encouragement and motivation for smoking cessation, 
especially if abnormal Spirometry is obtained (provides a 
teachable moment'). 
• Feedback to the patient about their disease and effect of 
medication. 
• More accurate and comprehensive assessment than peak flow. 
 
Definitions of common spirometric indices 
 FVC (Forced Vital Capacity) is the maximum volume of air that 
can be expired (or inspired) during a maneuvers using maximal 
effort. 
 SVC (Slow Vital Capacity) is the maximum volume of air that 
can be exhaled "slowly" following a full inspiration (or inhaled 
after a complete expiration). The SVC is similar to the FVC in 
subjects without airflow obstruction, but is often larger in 
subjects with airflow obstruction. 
 FEV1 (Forced Expired Volume in one second) is the volume of 
air that can be forcefully expired in the first second of the 
maximal expiration. It is a measure of how quickly full lungs 
can be emptied. 
  FEV1/FVC ratio is the FEV1 expressed as a percentage of the 
FVC and gives a clinically useful indicator of airflow 
obstruction. 
 FEF25-75% (Forced Expiratory Flow between 25 and 75 percent 
of the FVC) is the average expired flow over the middle half of 
the FVC maneuvers. It is regarded as a more sensitive but more 
variable measure of narrowing of the smaller airways than 
provided by FEV1. 
 
How to perform Spirometry 
 Spirometry requires maximal effort from the patient and it takes time 
to perform quality Spirometry. It is essential the procedure is carefully and 
clearly explained and to actively persuade and motivate the patient to perform 
maximally. The volume and flow parameters measured are defined in terms of 
maximal effort and maximal exhaled volume. The performance of Spirometry 
while seated upright in a chair is preferable to standing as this is the most 
stable position should the patient experience dizziness during the test. The 
seated position is also preferable for patients with urinary incontinence who 
may otherwise limit the expiratory effort. 
 
The key steps are to urge the patient to: 
 Breathe in fully (the lungs must be absolutely full). 
 Seal the lips around the mouth piece and blow immediately. 
 Blow the air out as fast and as far as possible until the lungs are 
completely empty. 
  Repeat the test until three acceptable and reproducible results 
are obtained (up to a maximum of 8 efforts) 
 The highest FEV1 and FVC should be reported, even if they 
come from separate blows. 
 
While it is not mandatory to use nose clips to prevent loss of measured 
volume through the nose, their use is sometimes of benefit. 
 
Acceptable Results and Real-time Display 
 Acceptable results are those that were initiated at full lung inflation, 
and with maximum expiratory effort (e.g. No hesitation at the start and no 
pauses throughout the blow) until no more air can be expired. The results are 
reproducible if there is less than 200 ml variation in FEV1 and FVC between 
the two best blows. 
 
 A spirometer that allows you to see a graph of the flow – volume curve 
in real time and provides alert messages about test quality makes it much 
easier to determine the acceptability of each blow. It is preferable to have both 
flow – volume and volume – time graphic outputs so that the acceptability of 
the results can be easily judged. 
 
Common Causes of Poor Quality Spirometry 
 Sub – maximal effort (e.g. Due to poor coaching, full bladder) 
 Failure to fully inflate the lungs prior to performing the forced 
expiration. 
  Incomplete expiration. 
 Hesitation at the start of the expiration. 
 Leaks (e.g. Between the lips and mouthpiece) 
 Poorly calibrated / maintained spirometer. 
 Untrained (or poorly) trained operator. 
 Inability to comprehend the instructions. 
 Cough 
 Glottic closure 
 Obstruction of the mouth piece by the tongue or teeth 
 Vocalization during the forced maneuver 
 Poor posture  
 
Examples of poorly performed Spirometry are shown in Figure 1and 2. 
 
Contraindications for Spirometry 
 Spirometry is a very safe procedure. However, it is physically 
demanding as it requires maximal patient effort and it involves the generation 
of high airway and intrathoracic pressures. It is advisable that Spirometry be 
delayed / abandoned for. 
 Recent eye surgery 
 Recent thoracic and abdominal surgery 
 Aneurysms (e.g. Cerebral, abdominal) 
 Unstable cardiac function 
 Haemoptysis of unknown cause (e.g. TB) 
 Pneumothorax 
  Chest and abdominal pain 
 Nausea and diarrhoea 
 Inability to comprehend the instructions 
 
Additionally children below the age of 7 years may have difficulty 
performing the test consistently. 
 
Interpretive Strategies 
 Figure 3 shows a simple algorithm to guide the interpretation of 
Spirometry results. In the first instance, interpretation should be based on the 
FEV1/FVC ratio. FEV1, and FVC to determine if the results demonstrate 
normal, obstructive, restrictive or mixed patterns. Categorizing the severity of 
an obstructive defect should be based on the percent predicted FEV1 rather 
than the FEV1/FVC ratio. 
 There are three classifications for abnormal Spirometry ( figure 4): 
 
 Obstructive Ventilatory Defect: characterized by reduced 
expiratory flows e.g. Reduced FEV1/FVC ratio, FEV1, FEF25-75% 
or if the expiratory flow volume curve is scooped out. common 
examples include asthma and COPD. 
 
 Restrictive Ventilatory Defect: characterised by loss of lung 
volume in the absence of airflow obstruction – i.e. as suggested 
by a low SVC or FVC but normal or high FEV1/FVC ratio. 
Examples include interstitial lung disease, respiratory muscle 
weakness, and thoracic cage deformities. 
 
 Mixed obstructive and Restrictive Ventilatory Defect:     
characterized by both airflow obstruction and loss of lung 
volume. i.e. a low FEV1/FVC ratio and low SVC or FVC. An 
example is cystic fibrosis. 
 
Additionally, certain respiratory conditions alter the shape of the flow 
volume loop and it is important to learn how to recognise these. Examples are 
given in Figure 5. 
 
The normal flow volume time curve shown together with examples of 
how respiratory disease can alter the shape of the flow volume relationship 
 
 
 a) Flow volume loop from a healthy subject. 
b) Obstructive airway disease (e.g. asthma) before (shaded curve) 
and after (dashed line) the administration of a bronchodilator. 
c) Severe obstructive disease (e.g. emphysema) before (shaded 
curve) and after (dashed line) the administration of a 
bronchodilator. 
d) Restrictive lung disease (e.g. pulmonary fibrosis) – the 
predicted FVC is marked. 
e) Fixed major airway obstruction (e.g. laryngeal obstruction). 
 
Asthma and COPD 
 In these diseases FEV1/FVC, and percent predicted FEV1 are critical to 
detect and grade the severity of airflow obstruction, respectively and are used 
in the interpretation algorithm (figure 3). Although both asthma and COPD 
are characterised by airflow obstruction, the mechanisms of each disease are 
different in COPD due to emphysema, airway obstruction is predominantly 
due to airway collapse whereas in asthma it is mainly due to 
bronchoconstriction, inflammation of the airway wall and mucous plugging.  
 
In general, Spirometry improves significantly after effective treatment 
in asthma but not at all, or only marginally, in patients with COPD although 
their symptoms may improve. 
 
 Reversibility of Airflow Obstruction 
 If there is evidence of airflow obstruction, Spirometry is usually 
performed and after the administration of a short – acting bronchodilator to 
assess whether the airflow obstruction can be reversed. 
 Perform pre-bronchodilator Spirometry  
 Administer the bronchodilator (e.g. 4 puffs of salbutamol via a 
spacer) 
 Wait 10 minutes 
 Perform post bronchodilator Spirometry  
 
If the clinical reason for performing the reversibility test was to check 
the patient's usual response to bronchodilator, it may be more appropriate to 
use the patient's usual bronchodilator device and dose. During this test it is 
helpful to observe the patient's normal inhaler technique and correct any 
errors. 
 
The American thoracic society recommends the following criteria for a 
significant improvement in Spirometry at least a 12% improvement in 
measured FEV1 (or FVC) and an absolute improvement of atleast 200ml in 
either of these two measures. 
 
It is important to note that in some patients the degree of reversibility 
can vary between clinic visits and will be reduced if the patient has taken a 
bronchodilator within prior to testing. It is important to ask the patient when 
 they last used their bronchodilator (short and long acting) and to take this into 
account when assessing the degree of reversibility. 
 
The absence of significant reversibility does not necessarily exclude 
the diagnosis of asthma. 
 
Note that the FEV1/FVC ratio is not a reliable index of reversibility as 
the FVC can increase more than FEV1 causing the FEV1/FVC ratio to 
decrease in the presence of a useful degree of bronchodilatation. Do not use 
FEF25-75% for assessing reversibility. 
 
Reversibility may also be assessed by measuring Spirometry before 
and several weeks after a trial of inhaled. 
 
Lung volumes and capacities (figure 7) 
 There are four lung volumes and four lung capacities30. 
 
Lung volumes31 
1. Tidal volume (TV) – is the volume of air that is inhaled or 
exhaled from the lungs during effortless breathing. 
2. Inspiratory reserve volume (IRV) – is the maximum volume 
of air that can be inhaled after the tidal volume is inhaled. 
3. Expiratory reserve volume (ERV) – is the amount of gas that 
can be exhaled from the lungs after a normal quiet exhalation. 
4. Residual volume (RV) – is the volume of gas remaining in the 
lungs after a complete maximal exhalation. 
 
 Lung capacities 
 In describing events of pulmonary cycle, it is desirable to consider two 
or more of the above volumes such combinations are called capacities. They 
are 
a) Inspiratory capacity (IC) – is the maximum amount of gas that can 
be inhaled after a normal, effortless exhalation. The Inspiratory 
capacity is the sum of the tidal volume and Inspiratory reserve volume. 
IC = VT + IRV 
 
b) Functional residual capacity (FRC) – is the amount of gas left in the 
lungs after a normal effortless exhalation at the resting expiratory level, 
the functional residual capacity equals. The sum of the expiratory 
reserve volume and the residual volume  
FRC  = ERV + RV 
 
c) Vital capacity (VC) – is the maximum amount of gas that can be 
exhaled after a maximum inhalation (or the maximum amount of gas 
that can be inhaled following a maximum exhalation). The vital 
capacity equals the sum of the Inspiratory reserve volume, the tidal 
volume and the expiratory reserve volume  
VC = IRV + VT + ERV 
 
d) Total lung capacity (TLC) – is the maximum volume of gas in the 
lungs at the end of a maximum inhalation. The total lung capacity 
equals the sum of all four lung volumes. 
TLC = IRV + VT + ERV + RV 
 (or) 
the sum of the vital capacity and the residual volume 
TLC = VC + RV 
(or) 
the sum of the functional residual capacity and the respiratory capacity 
TLC = FRC + IC 
 
All pulmonary volumes and capacities are about 20-25% less in 
women than in men and they are obviously greater in large and athletic person 
than in small and asthenic persons. 
 
                                              Flow Rates 
 
Forced Vital Capacity (FVC) 
 The maximum volume of air than can be expired or inspired during a 
forced expiratory maneuver initiated from TLC or RV. 
 
Forced expiratory volume in 1 second (FEV1) 
 It is the maximum volume of gas that the patient can exhaled during 
the first second of the forced vital capacity maneuver. 
 
Forced expiratory volume in 3 seconds (FEV3) 
It is the maximum volume of gas that the patient can exhaled during 
the three seconds of the forced vital capacity maneuver 
 
 The forced expiratory volume in 1 second ratio (% FEV1/FVC) 
  It is the percent of the measured forced vital capacity that can be 
exhaled in 1 second. 
 
Peak expiratory flow rate (PEFR) 
 It is the maximum, greatest expiratory flow rate in L/sec. The forced 
expiratory flow between 200 ml and 1200 ml (FEF200-1200) is a measure of the 
average expiratory flow during the early phase of exhalation; especially it is a 
measure of two flow rates for the 1000 ml of expired gas immediately 
following the first 200 ml of expired gas. This measurement is called the 
maximum expiratory flow rate (MEFR). 
 
The forced expiratory flow between 25% and 75% of the Forced vital 
capacity (FEF25-75%) 
 It is a measure of the average expiratory flow during the middle half of 
the forced vital capacity. 
 
The forced expiratory flow at 25% (FEF25% or Vmax 25) 
 It is the maximum expiratory flow after 25% of the forced vital 
capacity has been exhaled. 
 
The forced expiratory flow at 50% (FEF50% or Vmax50) 
 It is the maximum expiratory flow after 50% of the forced vital 
capacity has been exhaled. 
 
 The forced expiratory flow at 75% (FEF75% or Vmax75) 
 It is the maximum expiratory flow after 75% of the forced vital 
capacity has been exhaled. The forced Inspiratory flow at 50% (FIF 50%) of 
the vital capacity is the maximum Inspiratory flow after 50% of the forced 
vital capacity has been inspired. 
 
The maximum voluntary ventilation (MVV) is the maximum value of 
air in liters per minute that a subject can breathe during a 12 to 15 second 
period. The MVV was called the maximum breathing capacity (MBC). 
 
Although peak flow is largely a function of the caliber of the airway, it 
also greatly depends on expiratory muscle strength and on the patient's effort 
and coordination. As a result the measurement can be variable. In contrast 
high degrees of effort are not required to achieve maximum expiratory flow at 
intermediate and low lung volumes during forced expiration. Flow is often 
measured over the middle halt of the FVC (FEF25-75%=Maximum mid 
expiratory flow (MMEF) Because the flow does not include the initial, highly 
effort dependent portion of forced expiration, FEF25%-75% is often referred to 
as effort independent, values for FEF25%-75% in healthy young men average 4.5 
to 5.0 L/sec. It is a sensitive indicator of early obstruction in the small distal 
airway32 . 
 
Measurement of diffusion capacity33  
 The diffusing capacity DLCO is a measure of the lung's ability to 
transfer gas from alveoli to blood. The test utilizes uptake of carbon 
monoxide from a single breath of 0.3% mixture in air; this gas is chosen 
 because it combines rapidly with haemoglobin and provides a true estimate of 
diffusion across the alveolar capillary membrane. 
 
 The diffusion capacity is reduced in patients with disease principally 
affecting alveoli such as fibrosing alveolitis or emphysema. The transfer 
coefficient (KCO) is a measure of diffusing capacity expressed per volume of 
ventilated lung during the single breath test and is useful to contain that a low 
DLCO is due to alveolar disease rather than maldistribution of ventilation. 
High values of DLCO may be seen in alveolar haemorrhage. 
 
Arterial blood gas 
 The most commonly used measures of the gas exchange are the partial 
pressure of O2 and CO2 in arterial blood i.e. PaO2 and PaO2. These partial 
pressures do not measure directly the quantity of O2 or CO2 in blood but 
rather the driving pressure for the gas in blood. 
 
Pulse Oximetry 
 Measures oxygen saturation rather than PaO2 by using a probe clipped 
over patients finger. The device measures two wave lengths of light reflected 
by hemoglobin via pulsatile, cutaneous arterial blood. Because of differential 
absorption of the two wave lengths of light by oxygenated and non 
oxygenated haemoglobin, the percentage of haemoglobin that is saturated 
with O2 i.e. the SaO2 can be calculated and displayed instantaneously.  
  
 
 
 
 
MATERIALS AND 
METHODS 
 MATERIALS AND METHODS 
 
 This is a cross sectional, case control study conducted at Govt. Rajaji 
Hospital, Madurai between July 2005 to June 2006. The study was conducted 
on patients attending Medical OPD of Govt. Rajaji Hospital (GRH), Madurai. 
 
The study population was divided into four groups. 
1. Group I consist of patient who smoked less than 20 pack years and 
attended OPD for respiratory or non respiratory symptoms. 
2. Group II consist of patient who smoked 20-30 pack years and 
attended OPD for respiratory or non respiratory symptoms. 
3. Group III consist of patient who smoked 30 pack years and 
attended OPD for respiratory or non respiratory symptoms. 
4. Control group consists of non smokers with in the age group of 30 
to 65 years. 
 
Inclusion Criteria 
 Chronic male smokers who smoked for more than 10 years and age 
between 30 years to 65 years, irrespective of whether respiratory symptoms 
were present or not, were included in the study. 
 
Exclusion Criteria 
1. Obesity 
2. Anaemia 
3. Chest wall deformity – kyphosis, scoliosis, ankylosing spondylitis 
 4. Bronchial asthma 
5. Current / past pulmonary tuberculosis 
6. Patients with occupation prone to develop occupational lung disease 
7. Hypothyroidism 
8. Severe disease interfering with performance of pulmonary function test 
 
The selected patient were evaluated with a detailed history regarding 
duration of smoking, type of smoke, quantity, occupation history, drug 
history, respiratory symptoms like cough, expectoration, breathlessness. 
 
A detailed respiratory system examination with special attention to 
breath sound, crepitations and wheeze was done. 
 
The following basic investigation was done for all patients. 
1. Total WBC count 
2. Differential count 
3. Haemoglobin in Gm% 
4. Sputum examination for AFB 
5. Chest X Ray 
6. ECG 
 
After assessing these baseline clinical and laboratory parameters, the 
chronic smokers and control group were subjected to computerized 
spirometric evaluation. 
 
 All the spirometric parameters were expressed as percentage of 
predicted value for that particular age, sex, height and weight comparable to 
South Indian Population defined by Knudsen et al. 
 
All the tests were repeated on three occasions and the best of the three 
reading are taken. 
 
Among the various spirometric parameters, the following were 
analysed. 
1. Forced vital capacity (FVC) 
2. Forced Expiratory Volume in First Second (FEV1) 
3. Percentage of FVC, expelled as FEV1 
FEV1  x 100 
FVC 
4. Forced expiratory flow rate 50% the total FVC (FEF50) 
5. Forced expiratory flow rate between 25% and 75% of total FVC 
(FEF25-75%) also called maximal mid expiratory flow rate 
(MMEFR). 
 
The Spirometry was performed using Knudsen's computerized 
spirometer. 
 
Interpretation 
 The spirometric values are interpreted as pulmonary dysfunction in one 
of the following categories. Because there is some variability in normal 
individuals, values between 80% and 120% are considered normal and values 
 of individual measurement falling below the fifth percentile are considered to 
be below normal. 
 Normal value for FEV1 is around 83% 34 
 Normal value for FEV1/FVC is 75-85% 
 The FEF25-75% is often considered a more sensitive measurement 
of early small airway obstruction. 
 
Spirometric assessment allows categorization of pulmonary 
dysfunction into 
1. Obstructive pattern 
2. Restrictive pattern 
3. Mixed pattern 
 
Pattern FEV1 FVC FEV1/FVC 
Obstructive Decreased Normal 
(80-120%) 
Decreased (<75%) 
Restrictive Normal (or) 
Decreased 
Decreased 
(<80%) 
Normal or 
Increased (>75%) 
Mixed Normal or 
decreased 
Decreased 
(<80%) 
Decreased (<75%) 
 
  
 
 Obstructive pattern is further classified according to GOLD35,36,37 
Criteria (GOLD = Global Initiative for Chronic Obstructive Lung Disease). 
 
GOLD Criteria consist of four categories as follows38 
 
Spirometry GOLD 
Stage 
Severity Symptoms 
FEV1/FVC FEV1% 
0 At risk  Chronic cough, sputum 
production 
Normal  
I Mild With or without chronic 
cough or sputum 
production 
< 0.7 >80% predicted 
II Moderate With or without cough or 
sputum production 
< 0.7 50%-30% of 
predicted 
III Severe With or without chronic 
cough or sputum 
production 
< 0.7 30%-50% of 
predicted 
1. <0.7 <30% of predicted IV Very 
severe 
With or without chronic 
cough or sputum 
production 
                    Or 
2. FEV1< 50% of predicted with   
     respiratory failure or signs of    
     right heart failure. 
 
 Limitation of this study 
 Though carefully designed and meticulously carried out the study is 
subjected to subject (patient) error, instrument error and investigators 
error. 
 Since this study, does not include hospitalized, seriously ill patient, the 
magnitude of smoking related lung problems is not completely known. 
 
Statistical analysis 
Computer Analysis of Statistical data was done utilizing 
Epidemiological Information Package (EPI 2005) developed by World Health 
Organisation. Frequencies, percentages, mean, S.D. and ‘p’ values were 
calculated using this package. 
 
If the value of ‘p’ is less than <0.05, it is considered to be significant. 
 Statistical Analysis of Pulmonary Function Test in 
Chronics Smoker 
 
The study population consists of Four Groups 
 Group I : 36 smokers of 11-20 pack years. 
 Group II : 50 smokers of 21-30 pack years. 
 Group III : 64 smokers of > 30 pack years. 
 Group IV : 50 non smokers as control 
 
 Among the 36 smokers in Group I, all of them had normal pulmonary 
function test. There mean FEV1, were 85.1% mean FVC were 106.2%, mean 
FEV1/FVC were 80.2%, Mean FEF50 were 84.6% and mean FEF 25-75 were 
84.6%. 
 
 Among the smokers in Group II, 41 (82%) had normal pulmonary 
function test, 8(16%) had GOLD Stage I airflow obstruction, 1(2%) had 
GOLD Stage II airflow obstruction. There mean FEV1 were 84.6% mean FVC 
were 110.1%, Mean FEV1/FVC were 77.1%, Mean FEF50 were 81.9% and 
mean FEF25-75 were 82.2%. 
 
 Among the 64 smokers in Group III, 30 (46.8%) had normal 
pulmonary function test, 21 (32.8%) had GOLD stage I airflow obstruction, 6 
 (9.4%) had GOLD stage II airflow obstruction, 4 (6.3%) had restrictive 
pattern and 3 (4.7%) had mixed pattern. The mean FEV1, were 80.8%, Mean 
FVC were 107.5%, Mean FEV1/FVC were 76.4%, mean FEF50 were 80.2%, 
Mean FEF 25-75 were 80.3%. 
 
 Among the 50 non smokers in Group IV, 48 (96%) had normal 
pulmonary function test and 2(4%) had GOLD stage I airflow obstruction. 
There mean FEV1, were 82.5%, Mean FVC1 were 106.6%, Mean FEV1/FVC 
were 78.8, Mean FEF50 were 81.7% and Mean FEF 25-75 were 81.4%. 
 
 If all the smokers including normal PFT and abnormal PFT were 
considered there mean FEV1 were 83.11%, Mean FVC were 108.06%, Mean 
FEV1/FVC were 77.55% and Mean FEF50 were 81.82% and Mean FEF 25-75 
were 82.0%. 
 
 Similarly  nonsmokers including normal PFT and abnormal PFT were 
considered there mean FEV1, were 82.53%, Mean FVC were 106.6%, Mean 
FEV1/FVC were 78.8%, Mean FEF50 were 81.74 and mean FEF25-75 were 
81.44%.. 
  
 
 
 
 
RESULTS 
 RESULTS 
 
A. Comparison of parameters in the Study Group (Chronic Smokers) 
and Control Group (Non Smokers). 
 
Table 1  
Age distribution of study groups and control groups 
 
Study Group 
(Smokers) 
Control Group 
(Non Smokers) 
Age Group 
No % No % 
< 40 29 19.3 6 12 
41 – 50 33 22.0 14 28 
51 – 60 57 38.0 16 32 
> 60 31 20.7 14 28 
Total 150 100 50 100 
Mean 50.7 yrs 53.6 yrs 
S.D 10.4 10.9 
P 0.1818 
 
 There is no statistically significant difference in the age composition of 
the two groups. 
 
 Table : 2 
 
Coughing in Smoker and Non smokers 
 
Study Group 
(Smokers) 
Control Group 
(Non Smokers) 
Cough 
No % No % 
Present 46 30.7 5 10 
Absent 104 69.3 45 90 
 
 
‘P = 0.0066 (Significant) 
 
 The percentage of persons reporting cough is more in smokers then in 
non-smokers. The difference is statistically significant 
 
 Table :3 
 
Mean FEV1, FVC, FEV1/FVC % FEF 50 and FEF 25-75 of smokers and 
non smokers 
 
Smokers Non Smokers Parameter 
Mean S.D Mean S.D 
P 
FEV1 % 83.11 5.97 82.53 6.0 0.3199 
FVC % 108.06 10.07 106.6 13.12 0.9944 
FEV1/FVC%  77.55 8.98 78.8 5.78 0.7264 
FEF 50 81.82 5.57 81.74 5.78 0.9616 
FEF 25-75 82.0 5.77 81.44 5.79 0.5181 
 
 There is no statistically significant difference in the pulmonary 
function parameters of smokers and nonsmokers. 
 
 Table 4  
 
Pulmonary function  status of smokers and non smokers 
 
Smokers Non Smokers 
(control) 
Pulmonary 
function Status 
No. % No. % 
Normal 107 71.3 48 96 
GOLD stage I 29 19.3 2 4 
GOLD Stage II 7 4.7 - - 
Restrictive 4 2.7 - - 
Mixed 3 2 - - 
Total  150 100 50 100 
 
‘p’ = 0.0006 
 
 There is   statistically significant difference in the pulmonary function 
status of smokers and nonsmokers. 
 
 B. Characteristics of the Study Group 
 
Table 5 
Pack years of smokers 
 
Smokers Pack Years 
No. % 
11-20 36 24 
21-30 50 33.3 
>30 64 42.7 
Total 150 100 
Mean 
S.D. 
30.8 
12.8 
 
The mean pack years of the smokers were 30.8. 
 Table 6 
 
Distribution of pulmonary function  
status in smokers 
 
smokers Pulmonary function  Status 
No. % 
Normal 107 71.3 
GOLD stage I 29 19.3 
GOLD Stage II 7 4.7 
Restrictive 4 2.7 
Mixed 3 2 
Total  150 100 
 
 
Among the smokers studied, 28.7% had abnormal pulmonary function 
status.  
 Table7 
 
Mean FEV1, FVC, FEV1/FVC (%), FEF50  
and FEF25-75 of smokers 
 
Smoker Parameter 
Mean S.D. 
FEV1 % 83.1 6 
FVC % 108.1 10.1 
FEV1/FVC % 77.5 9 
FEF 50 81.8 5.6 
FEF 25-75 81.9 5.6 
 
 C. Relationship of parameters in the Study Group 
 
Table 8  
Age and Pack years 
 
Pack Years 
11-20 21-30 >30 Total 
Age Group 
No. % No. % No. % Mean S.D. 
31-40 18 50 10 20 1 1.6 19.2 6.2 
41-50 11 30.6 11 22 11 17.2 26.1 9.2 
51-60 4 11.1 19 38 34 53.1 36.4 12.2 
>60 3 8.3 10 20 18 28.1 36.3 13 
Total 36 100 50 100 100 100 30.8 12.8 
‘p’ 0.0001 
 
Statistically significant relationship exists between age and pack years. 
It is highest in the ‘more than 50’ age group. 
 Table 9 
Age and pulmonary function status 
 
Pulmonary function status 
Normal Stage I Stage II Restrictive Mixed Total 
Age 
Group 
No. % No. % No. % No. % No. % No. % 
31-40 26 24.3 2 6.9 1 14.3 - - - - 29 19.3 
41-50 24 22.4 7 24.1 1 14.3 1 25 - - 33 22 
51-60 38 35.5 12 41.4 3 42.9 2 50 2 66.7 57 38 
>60 19 17.8 8 27.6 2 28.6 1 25 1 33.3 31 20.1 
Total 107 100 29 100 7 100 4 100 3 100 150 100 
Mean 
age 
S.D. 
49.0 
 
10.8 
55.3 
 
10.1 
56.0 
 
11.3 
60.0 
 
9.4 
63.3 
 
10.1 
51.2 
 
11.1 
p 0.0056 
 
Abnormal pulmonary function was more prevalent in the older age 
group than the younger age group and this difference was statistically 
significant. 
 Table 10 
Mean values of FEV1, FVC, FEV1/FVC, FEF50 and  
FEF25-75 in different age groups 
 
FEV1 FVC FEV1/FVC FEF50 FEF25-75 Age 
Group Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D. 
31-40 84.5 4.3 108.3 5.6 78.1 5.3 83.3 4.6 83.2 4.4 
41-50 83.4 5.7 108.7 9.3 77.2 8.2 81.8 5.4 82.2 6.1 
51-60 82.7 6.8 107.5 11.8 77.7 10.3 81.6 6 81.6 6.1 
>60 82.4 6 108.1 11 77 10.3 80.9 5.8 81.2 6.5 
Total 83.6 6 108.1 10.1 77.5 9 81.8 5.6 81.9 5.9 
p 0.2605 0.8185 0.6836 0.6001 0.7307 
 
 The value of the parameters has no significant relationship with the age 
of the respondents. 
 Table 11 
Pack Years and Pulmonary function status 
 
Pulmonary function Status 
Normal Stage I Stage II Restrictive Mixed Total 
Pack 
years 
No. % No. % No. % No. % No. % No. % 
11-20 36 33.6 - - - - - - - - 36 24 
21-30 41 38.3 8 27.6 1 14.3 - - - - 50 33.3 
>30 30 28 21 72.4 6 85.7 4 100 3 100 64 42.7 
Total 107 150 29 100 7 100 100 100 3 100 150 100 
Mean 
pack 
years 
S.D. 
 
26.4 
 
10.4 
 
39.0 
 
10.7 
 
42.9 
 
10.7 
 
51.6 
 
15.6 
 
53.3 
 
5.8 
 
30.8 
 
12.8 
 
P = 0.0001 
 
 Severity of the obstruction is significantly affected by the pack years of 
the respondents. 
 
 Table 12  
Mean values of FEV1, FVC, FEV1/FVC, FEF50 and FEF25-75  
and pack years of smokers 
 
FEV1 FVC FEV1/FVC FEF50 FEF25-75 Pack 
years Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D. 
11-20 85.1 1.8 106.2 502 80.2 3.0 84.6 3.1 84.6 3.2 
21-30 84.6 3.4 110.1 506 77.1 5.3 81.9 4.9 82.2 5.1 
>30 80.8 8.0 107.5 14.0 76.4 12.6 80.2 6.5 80.3 7.0 
Total 83.1 6.0 108.1 10.1 77.5 9.0 81.8 5.6 81.9 5.9 
P 0.0002 0.0061 0.0003 0.0122 0.0384 
 
 There exists statistically significant relationship between the pack 
years and the pulmonary function parameters. 
 
 Table 13  
Mean values of FEV1, FVC, FEV1/FVC, FEF50 and FEF25-75 in smokers 
with abnormal pulmonary function status 
 
FEV1 FVC FEV1/FVC FEF50 FEF25-75 Pulmonary 
function  
Status 
Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D. 
Normal 85.5 1.7 108 5.2 79.3 3.0 84.6 2.8 84.7 3.1 
Stage I 81.2 0.8 118.2 1.5 68.7 1.1 74.3 0.8 74.0 1.0 
Stage II 59.8 6.2 102.2 7.5 58.4 2.1 72.8 1.7 72.6 1.7 
Restrictive 77.3 1.7 72.6 1.6 106.3 2.9 83.5 1.0 84.5 3.5 
Mixed 77.9 0.9 73.3 0.9 106.5 2.1 87.3 2.1 88.0 2.6 
Total 83.1 6.0 108.1 10.1 77.5 9.0 81.8 5.6 89.9 5.9 
P 0.0001 0.0001 0.0001 0.0001 0.0001 
 
‘p’ = 0.0001 (Significant). 
 
 
 
 
 
 
 
 
 
 Table 14 
Reporting of coughing in patients with different Pulmonary 
Function status 
 
Coughing  
Present Absent 
Total Pulmonary 
function 
Status No. % No. % No. % 
Normal 26 24.1 81 75.7 107 100 
GOLD Stage I 14 48.3 15 51.7 29 100 
GOLD Stage II 4 57.1 3 42.7 7 100 
Restrictive 2 50 2 50 4 100 
Mixed 1 33.3 2 66.7 3 100 
Abnormal Total 21 48.8 22 51.2 43 100 
 
P = 0.0062 (Significant). 
 
Gold stage II airflow obstruction and Restrictive lung disease smokers 
had more cough than other group. 
  
 
 
 
 
 
DISCUSSION 
 DISCUSSION 
 
Chronic obstructive pulmonary disease is characterized by the presence 
of chronic bronchitis and/or emphysema, which are mostly due to cigarette 
smoking. Airways and parenchyma are primarily affected regions showing the 
pathologic changes in the lungs. Spiro metric decline found to be related to 
the severity of COPD ( Mehmet Polath et al) 39. 
 
 In this study 150 male smokers [(Mean age 50.7 years (SD 10.4)] and 
50 male nonsmokers [(Mean age 53.6 years (SD 10.9] were studied recording 
pulmonary function test using spirometry. There were no statistically 
significant differences in the age composition of the two-study group. They 
came to the hospital for minor ailment. 
 
 Airflow obstruction were catogarized according to GOLD Criteria. 
Among the smoker studied 28.7% had abnormal pulmonary study pattern, 
71.3% had normal pulmonary function. This study was comparable to study 
conducted by Murrey RP et al40. In their study of 70,000 chronic smokers 
about 25% were found to have borderline to moderate airflow obstruction, 
additional 5% had severe airflow obstruction. 
 
  In this study, out of the 28.7% abnormal pulmonary function pattern, 
19.3% were in GOLD stage I airflow obstruction, 4.7% were in GOLD stage 
II airflow obstruction, 2.7% were in restrictive pulmonary pattern and 2% 
were in mixed pulmonary pattern. So most of the abnormality fall in GOLD 
stage I air flow obstructive pattern. Non of the smoker in this study were in 
GOLD stage III or IV. Previously undetected abnormal lung function in 
chronic smoker was detected of having abnormal pulmonary function pattern 
by using spirometry. 
 
 Roeland MM Geijer et al41 in their study of 702 chronic smoker, he 
had found 29.9% had abnormal pulmonary function test out of which mild 
airflow obstruction (GOLD Stage I) were in 25.9% and moderate airflow 
obstruction (GOLD stage II) were in 4%. This study was comparable to our 
study. 
 
 Among the nonsmoker studied (control) 96% had normal lung function 
test and 4% had GOLD stage I airflow obstruction. So there were statistically 
significant difference in pulmonary function status of smoker and 
nonsmokers. Smoker had abnormal pulmonary function more commonly then 
nonsmokers. Among the smokers obstructive airflow disease were more 
common than restrictive lung disease. This was compatible to Roeland MM 
heijer et al’s study. 
  In this study 24% of the smoker fall in 11-20 pack year category 
(Group-I), 33.3% of the smoker fall in 21-30 pack year category (Group II) 
and 42.7% of the smoker fall in >30 pack year category (Group III). The 
mean pack years of the smokers were 30.8 pack years. 
 
 In this study: 31-40 yrs age group most of the smoker were smoked for 
11-20 pack years (50%), 41-50yrs age group most of the smoker were smoked 
11-20 pack years (30.6%), in 51-60 yrs age group most of them were smoked 
>30 pack years (53.1%), > 60years age group most of them had smoked > 30 
pack years (28.1%). There was statistically significant relationship exists 
between age and pack years. Pack years is highest in above 50 age group. It 
indicates as age increases number of pack years also increases. 
 
 In the present study, in age group 31-40 years (total 29) 26 had normal 
pulmonary function status, 2 had GOLD stage I airflow obstruction, 1 had 
GOLD stage II airflow obstruction. In age group 41-50 years (Total33) – 24 
had normal pulmonary function, 7 had GOLD stage I airflow obstruction, 1 
had GOLD stage II airflow obstruction, 1 had restrictive pattern. 
 
 In age group 51-60 yrs (total 57) – 38 had normal pulmonary function, 
12 were GOLD stage I airflow obstruction, 3 were in gold stage II airflow 
obstruction, 2 were restrictive lung disease, 2 had mixed disease. 
  In age group > 60 yrs (total 31) – 19 were in  normal,8 were in GOLD 
stage I airflow obstruction, 2 were in GOLD stage II airflow obstruction, 1 
had restrictive lung disease. 1 had mixed lung disease. 
 
 Airway obstruction was more prevalent in the old age group ( >50 
years) the younger age group (<50years) and this difference was statistically 
significant. 
 
 Alfred PE Sachs et al42 in his study he found in the older age group 
(>55yrs) airflow obstruction (GOLD 1 or higher ) was found in 45% verses 
21% in the youngest age group (40-44yrs) our study correlate with his 
observations. 
 
In this study, among the smokers (150), 36 smokers were in the 11-20 
pack years group (24%) and they had normal pulmonary function status. 50 
smokers had 21-30 pack years group, out of whom 41 had normal pulmonary 
function. 8 had GOLD stage I airflow obstruction  only one and I had GOLD 
Stage II airflow obstruction.  
 
In more than 30 pack years group, 64 smokers were present in total out 
of whom 30 had normal pulmonary study. 21 had GOLD stage I airflow 
 obstruction, 6 had GOLD stage II airway obstruction 4 had restrictive pattern 
3 had mixed abnormality. 
 
 As the pack years increases, lung function abnormality become more 
obivious. It is statistically significant. 
 
Connett JE et al43 in his study he found that > 20 pack years of 
cigarette smoking was major risk factor for COPD. 
 
Jan willem J. Lamves et al44 in his study he noted smokers > 30, pack 
years the prevalence of airflow obstruction was 45% verses 20% among those 
with <20 pack years. 
 
 In the over all smokers population in this study (150)  
 107 smokers had normal function test. In them 77 
(71.9%) in < 30 pack years group. 30 (28%) smoker were 
>30 pack years group. 
 29 smoker had GOLD stage I airflow obstruction, out of 
which 8 (27.6%) were in <30 each years group, 21 
(72.4%) were in > 30 pack years group. 
  7 smoker had GOLD stage II airflow obstruction, out of 
which 1 (14.3%) were in < 30 pack years group, 6 
(85.7%) were in > 30 pack years group. 
 4smokers had Restrictive pattern all of them were > 30 
pack year group. 
 3 smoker had mixed pattern, all of them were >30 pack 
years group. 
 
From this observation < 20 pack years non of the smokers had 
significant lung function abnormality, 21-30 pack years had predominantly 
GOLD stage I airflow obstruction, > 30 pack years had predominantly GOLD 
State I airflow obstruction followed by GOLD stage II airflow obstruction. 
Restrictive pattern and mixed pattern were seen only in >30 pack years group. 
 
 In the smoker group (150) 47 smoker complaint of cough (31.3%) and 
103 smoker did not have cough. 
 26 smokers (24.1%) with normal lung function test had cough. 
 14 (48.3) out of 29 GOLD stage I had cough, 4 (57.1%) out of 7 
GOLD stage II airflow obstruction had cough. 
 2 (50%) out of 4 smoker in restrictive in restrict pattern had 
cough. 
 1(33.3%) out of 3 smoker in mixed pattern had cough. 
 From this observation, in GOLD stage II air flow obstruction and 
restrictive lung disease pattern had more cough than other group. 
 
 In the 107 smoker with normal pulmonary function test 81(75.7%) did 
not have cough, but 26 smoker (24.1%) had cough. Even with out airflow 
obstruction, person who had smoking habit had cough. 
 
 Arno W Hoes et al45, in their study smoker reporting coughing the 
prevalence was 47% versus 25% in those not reporting this symptom. 
 
 In out study smoker reporting coughing the prevalence was 44.6% 
versus 21.3% in those not reporting this symptoms. It was comparable to 
previous study. 
 
David. A. Kaminsky et al, Theodore W. Marcy et al46 they found those 
smokers who had moderate and severe airflow limitation on spirometric 
screening were more likely to have quit smoking compared to those with mild 
or no airflow limitation. The authors concluded that the diagnosis of airflow 
limitation motivated smokers to attempt to quit smoking. 
 
J.E. connett et al47 in their study of 3926 smoker with mild-moderate 
airflow obstruction, concluded that smoker airflow obstruction benefit from 
quitting despite previous heavy smoking, advanced age, poor base line lung 
function or airway hyper responsiveness. 
  
 
 
 
 
CONCLUSION 
 CONCLUSION 
 
 
1. High prevalence of pulmonary function abnormalities (28.7%) was 
seen in chronic smokers. 
 
2. GOLD stage I airflow obstruction was observed in 19.3% of the 
chronic smokers. 
 
3. Gold stage II airflow obstruction was observed in 4.7% of the chronic 
smokers. 
 
4. Restrictive pulmonary pattern was observed in 2.7% of the chronic 
smokers. 
 
5. Mixed pulmonary pattern was observed in 2% of the chronic smokers. 
 
6. Smoker had abnormal lung function more commonly than nonsmokers. 
 
7. Pack years of smoking was highest in >50yrs age group. As age 
increases number of pack years also increases. 
  
8. Airflow obstruction was more prevalent in the old age group (>50yrs) 
than the <50 yrs group. 
 
9. As the pack years increases lung function abnormality also increases. 
 
10. Restrictive pattern and mixed pattern were seen in >30 pack years 
smoker group only. 
 
11. Gold stage II airflow obstruction and Restrictive lung disease smokers 
had more cough than other group. 
 
12. Among the smoker who had abnormal pulmonary function test 48.8% 
had complaints of cough. 
 
 
In summary, spirometry detects undetected pulmonary function 
abnormality – both airflow obstruction and restrictive lung disease in the 
chronic smokers. 
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PROFORMA 
 PROFORMA 
 
PULMONARY FUNCTION TEST IN CHRONIC SMOKERS 
 
Name  :     Smoking Habit : 
Age  :      Type   : 
Sex  :       Cigarettes 
Occupation :       Cigar 
       Beedi 
 
 
Address :     Duration 
 
Height :     Quantity 
Weight : 
 
Symptoms    Sign 
 Cough     Pallor 
 Expectoration   Erythrocytosis 
 Hemoptysis    Clubbing 
 Wheezing    Obesity 
 Chest pain    Malnutrition 
      Fever 
      Tachycardia 
      Cor pulmonale 
 
 
 
 
 AUSCULATORY FINDING 
                 CVS  
                   RS 
 
Co-existing disease 
    
Lung disease 
a. Bronchial asthma 
b. Tuberculosis 
c. ILD 
d. Pleural effusion 
 
CVS 
e. CHD 
f. IHD 
g. HT 
 
CNS 
h. Disorientation 
i. Mental State 
j. Intoxication 
 
Endocrine 
k. Hypothyroidism 
l. Diabetes 
 
Orthopedic 
m. Kyphoscohosis 
n. Chest wall deformity 
  
Connective tissue disorder 
o. Ankylosing spondylosis 
p. Rhematoid arthritis 
q. SLE 
Malignancy 
II. Renal Disease 
 
Investigation 
1. Hb 
2. TC 
3. DC 
4. Sputum AFB 
5. X-ray Chest 
6. ECG 
 
Spirometry 
 
Spirometric Parameter % of predicted value 
FEV1  
FVC  
FEV1/FVC  
FEF50%  
FEF25-75%  
 
 
 
 
 
  
 
 
 
ABBREVIATIONS 
 ABBREVIATIONS 
 
COPD  - Chronic Obstructive Pulmonary Disease 
CHD  - Coronary Heart Disease 
CNS  - Central Nervous System 
DLco  - Diffusing Lung Capacity for Carbon Monoxide 
ERV  - Expiratory Reserve Volume 
FEV1  - Forced Vital Capacity in one second 
FEF50% - Forced Expiratory Flow at 50% of Vital Capacity 
FEF25-75%  - Forced Expiratory Flow at 25to75% of Vital Capacity 
FIF50% - Forced Inspiratory Flow at 50% of Vital Capacity 
FRC  - Functional Residual Capacity 
FVC  - Forced Vital Capacity 
GOLD - Global Initiative for Chronic Obstructive Lung Disease 
HDL  - High Density Lipoprotein 
IRV  - Inspiratory Reserve Volume 
IC  - Inspiratory Capacity 
ILD  - Interstitial Lung Disease 
IHD  - Ischemic Heart Disease 
LDL  - Low Density Lipoprotein 
MBC  - Maximum Breathing Capacity 
MI  - Myocardial Infarction 
 MMEFR - Mid Maximal Expiratory Flow Rate 
MVV  - Maximum Voluntary Ventilation 
PEFR  - Peak Expiratory Flow Rate 
PFT  - Pulmonary Function Tests 
RV  - Residual Volume 
SVS  - Slow Vital Capacity 
TAO  - Thromboangitis obliterans  
TLC  - Total Lung Capacity 
TV  - Tidal Volume 
VC  - Vital Capacity 
  
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Pulmonary function status of smokers and non smokers
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Distribution of pulmonary function status in smoker 
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Age and pulmonary function status of smokers
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Pack Years and pulmonary function status of smokers
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Mean values of FEV1, FVC, FEV1/FVC, FEF50
and FEF25-75 in smokers with abnormal 
pulmonary function status
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SPIROMETRY 
SMOKER PERFORMING SPIROMETRY 
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Figure 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
Figure 2 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 3 
 
Guideline for Spirometry Interpretation27,28,29 
 
Is FEV1/FVC < Lower Limit of Predicted?  No 
 
 
Is FVC < Lower Limit of  
Predicted? 
  Yes 
 
         Yes           No 
Assess Severity of Obstruction 
Using % Predicted FEV1 
 
Asthma* 
Mild Obstruction > 80%     Restrictive pattern           Spirometry within 
Moderate obstruction 80% to 60%    (Suggest referral for  Normal limits of 
Severe obstruction < 60%     confirmation of            Reference values 
        Diagnosis) 
COPD^ (Post bronchodilator) 
Mild Obstruction > 60%   
Moderate obstruction 60% to 40% 
Severe obstruction < 40%   
 
 
 
 
 
  
 
 
 
 
 
 
Figure 4 
Generalised Classification of Ventilatory defects 
 
 
 
Obstructive Ventilatory Defect Normal 
 
 
 
Mixed Ventilatory Defect  
 
(NOTE: Could be obstructive only if the 
low FVC (or VC) is due to airway closure, 
breathlessness etc.) 
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Ventilatory 
Defect 
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Figure 6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
O - Obstructive Disease 
R (P) - Restrictive Parenchymal 
R (E) - Restrictive Extraparenchymal 
TLC - Total Lung Capacity 
RV - Residual Volume 
  
Figure 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Volume (L) 
  Men Women  
Vital Capacity     IRV 
   TV 
   ERV 
RV 
3.3 
0.5 
1.0 
1.2 
1.9 
0.5 
0.7 
1.1 
Inspiratory capacity 
 
Functional Residual 
capacity 
Total Lung capacity 6.0 4.2  
 
Respiratory minute volume (rest) : 6 L/min  Timed vital capacity : 83% of total in 1 s; 97% in 3 s 
Alveolar ventilation (rest) : 4.2 L/min   Work of quiet breathing : 0.5 kg-m/min 
Maximal voluntary ventilation (BTPS) : 125-170 L/min Maximal work of breathing : 10 kg-m / breath 
 
 
 
  
 
MASTER CHART 
 
FEV1 Sl.No NAME AGE Pack years Cough Chest 
pain 
wheeze Dys 
pnoea 
Cre 
pitation 
rhonchai ECG X-RAY SPUTUM AFB FEV1% FVC% 
FVC 
FEV1 
FVC 
% 
FEF50 FEF25-75 TYPE 
1 Ramasamy 35 13 No - - - - - Normal Normal Negative 83.5 99 0.84 84.34 83 83 Normal 
2 Velayutham 47 18 No - - - - - Normal Normal Negative 85.6 110.5 0.77 77.47 81 90 Normal 
3 Karuppathevar 53 44 Yes - - - - - Normal Normal Negative 86.8 113.7 0.76 76.34 87 89 Normal 
4 Muthiah 51 60 No - - - - - Normal Normal Negative 80.9 120 0.67 67.42 70 71 Stage I 
5 Venkatraman 52 18 No - - - - - Normal Normal Negative 89.1 109.9 0.81 81.07 87 86 Normal 
6 Suresh 34 15 No - - - - - Normal Normal Negative 83.4 109 0.77 76.51 85 82 Normal 
7 Chellam 44 40 Yes - - - - - Normal Normal Negative 84.1 109.6 0.77 76.73 85 84 Normal 
8 Naguppillai 62 24 No - - - - - Normal Normal Negative 86.7 111 0.78 78.11 83 84 Normal 
9 Raju 53 40 Yes - - - - - Normal Normal Negative 81.5 119.2 0.68 68.37 73 72 Stage I 
10 Kundan 72 64 No - - - - - Normal Normal Negative 77 74.3 1.04 103.6 84 82 Restrictive 
11 Rangasamy 51 28 No - - - - - Normal Normal Negative 89 106.4 0.84 83.65 80 84 Normal 
12 Jeyaram 63 48 No - - - - - Normal Normal Negative 80.9 118.3 0.68 68.39 75 74 Stage I 
13 Ramu 60 45 Yes - - - - - Normal Normal Negative 78.4 72.6 1.08 108 82 81 Restrictive 
14 Muthukrishnan 42 16 No - - - - - Normal Normal Negative 83.7 99.9 0.84 83.78 88 85 Normal 
15 Veeranan 47 40 Yes - - - - - Normal Normal Negative 80.5 118.6 0.68 67.88 71 70 Stage I 
16 Govindan 51 48 No - - - - - Normal Normal Negative 84.8 105.5 0.8 80.38 87 85 Normal 
17 Vailumuthu 39 18 No - - - - - Normal Normal Negative 85.6 108 0.79 79.26 86 81 Normal 
18 Sudarsanam 45 28 Yes - - - - - Normal Normal Negative 81.7 118.8 0.69 68.77 73 73 Stage I 
19 Ponniah 52 25 No - - - - - Normal Normal Negative 84.9 105.3 0.81 80.63 86 87 Normal 
20 Periyagoundar 60 36 Yes - - - - - Normal Normal Negative 52.4 92.4 0.57 56.71 71 73 Stage II 
21 Lakshmanan 58 28 No - - - - - Normal Normal Negative 84.8 106.6 0.8 79.55 83 80 Normal 
22 Dharmar 45 40 Yes - - - - - Normal Normal Negative 84.9 109.4 0.78 77.61 83 87 Normal 
23 Ramalingam 32 18 No - - - - - Normal Normal Negative 83 98 0.85 84.69 81 87 Normal 
24 Subramani 49 30 No - - - - - Normal Normal Negative 80.2 119.2 0.67 67.28 73 74 Stage I 
25 Vellaiyan 68 40 Yes - - - - - Normal Normal Negative 82.1 120 0.68 68.42 73 72 Stage I 
26 Mani 68 32 No - - - - - Normal Normal Negative 85.2 107.8 0.79 79.04 82 84 Normal 
27 Marisamy 56 36 No - - - - - Normal Normal Negative 81.9 119.4 0.69 68.59 75 74 Stage I 
28 Nalluthevar 53 24 Yes - - - - - Normal Normal Negative 83.9 99.9 0.84 83.98 85 81 Normal 
FEV1 Sl.No NAME AGE Pack years Cough Chest 
pain 
wheeze Dys 
pnoea 
Cre 
pitation 
rhonchai ECG X-RAY SPUTUM AFB FEV1% FVC% 
FVC 
FEV1 
FVC 
% 
FEF50 FEF25-75 TYPE 
29 Chinnian 45 18 No - - - - - Normal Normal Negative 85.4 111.3 0.77 76.73 81 81 Normal 
30 Ranganathan 33 22 Yes - - - - - Normal Normal Negative 88.4 108 0.82 81.85 86 83 Normal 
31 Krishnamoorthi 58 44 No - - - - - Normal Normal Negative 85.1 111.6 0.76 76.25 90 84 Normal 
32 Varadhan 57 36 No - - - - - Normal Normal Negative 83.4 100.5 0.83 82.99 82 87 Normal 
33 Abraham 59 64 No - - - - - Normal Normal Negative 76.3 70.5 1.08 108.2 84 88 Restrictive 
34 Balusamy 62 44 Yes - - - - - Normal Normal Negative 85.9 109.6 0.78 78.38 83 80 Normal 
35 Arockiasamy 52 40 Yes - - - - - Normal Normal Negative 85.3 110.5 0.77 77.19 90 85 Normal 
36 Mujibur 58 21 No - - - - - Normal Normal Negative 84.8 106.6 0.8 79.55 83 80 Normal 
37 Thomas 59 33 Yes - - - - - Normal Normal Negative 81.5 116.9 0.7 69.72 75 72 Stage I 
38 Seeni 35 36 Yes - - - - - Normal Normal Negative 64.3 109.5 0.59 58.72 71 72 Stage II 
39 Kuttiyappan 41 30 No - - - - - Normal Normal Negative 84.7 107.4 0.79 78.86 88 82 Normal 
40 Abdullah 49 32 Yes - - - - - Normal Normal Negative 77.3 72.9 1.06 106 84 87 Restrictive 
41 Micheal 52 30 No - - - - - Normal Normal Negative 83.6 101.5 0.82 82.36 88 83 Normal 
42 Loganathan 57 50 No - - - - - Normal Normal Negative 75.9 73.4 1.03 103.4 88 87 Mixed 
43 Kannuchamy 61 44 Yes - - - - - Normal Normal Negative 83.2 99.9 0.83 83.28 88 89 Normal 
44 Joseph 55 45 No - - - - - Normal Normal Negative 80.7 116.2 0.69 69.45 74 75 Stage I 
45 Kannuthevar 31 26 No - - - - - Normal Normal Negative 88.1 114.4 0.77 77.01 88 80 Normal 
46 Subbunadar 36 30 No - - - - - Normal Normal Negative 86.5 115.3 0.75 75.02 82 85 Normal 
47 Arulraj 43 16 No - - - - - Normal Normal Negative 86.3 112.7 0.77 76.57 84 87 Normal 
48 Veeran 54 28 Yes - - - - - Normal Normal Negative 84.3 105.2 0.8 80.13 87 85 Normal 
49 Lakshmanan 56 40 Yes - - - - - Normal Normal Negative 87.1 118.2 0.74 73.69 84 90 Normal 
50 Usman 65 36 Yes - - - - - Normal Normal Negative 81.4 119.3 0.68 68.23 75 75 Stage I 
51 Kasi Viswanathan 36 30 Yes - - - - - Normal Normal Negative 83.7 104.5 0.8 80.1 82 88 Normal 
52 Logu 46 28 No - - - - - Normal Normal Negative 86.5 115.3 0.75 75.02 82 85 Normal 
53 Kannan 41 36 No - - - - - Normal Normal Negative 89.4 113.4 0.79 78.84 86 87 Normal 
54 Seenithevar 59 20 Yes - - - - - Normal Normal Negative 84.9 104.4 0.81 81.32 83 82 Normal 
55 Palani 52 36 No - - - - - Normal Normal Negative 83.6 102.1 0.82 81.88 85 90 Normal 
56 Singaram 62 48 No - - - - - Normal Normal Negative 84.7 109.4 0.77 77.42 88 87 Normal 
57 Dennis 64 30 No - - - - - Normal Normal Negative 83.8 103.3 0.81 81.12 85 86 Normal 
58 Arunachalam 54 15 Yes - - - - - Normal Normal Negative 83.7 101.1 0.83 82.79 90 84 Normal 
FEV1 Sl.No NAME AGE Pack years Cough Chest 
pain 
wheeze Dys 
pnoea 
Cre 
pitation 
rhonchai ECG X-RAY SPUTUM AFB FEV1% FVC% 
FVC 
FEV1 
FVC 
% 
FEF50 FEF25-75 TYPE 
59 Vellaisamy 59 28 No - - - - - Normal Normal Negative 84.2 111 0.76 75.86 87 81 Normal 
60 Peer Muhamed 65 32 No - - - - - Normal Normal Negative 89.9 113.2 0.79 79.42 83 81 Normal 
61 Subburaj 62 18 No - - - - - Normal Normal Negative 88 105.5 0.83 83.41 87 90 Normal 
62 Narayanan 41 32 No - - - - - Normal Normal Negative 85 111.8 0.76 76.03 87 86 Normal 
63 Thiruppathi 47 20 Yes - - - - - Normal Normal Negative 83.7 100.6 0.83 83.2 86 90 Normal 
64 Williams 34 22 No - - - - - Normal Normal Negative 86.7 109.9 0.79 78.89 88 81 Normal 
65 Palavesam 47 20 No - - - - - Normal Normal Negative 83.7 100.6 0.83 83.2 86 90 Normal 
66 Yousuf 55 32 No - - - - - Normal Normal Negative 85.5 109.3 0.78 78.23 88 83 Normal 
67 Panneer 65 15 Yes - - - - - Normal Normal Negative 84.4 107.2 0.79 78.73 81 84 Normal 
68 Nataraj 64 55 No - - - - - Normal Normal Negative 59 104 0.57 56.73 70 71 Stage II 
69 Martin 32 16 No - - - - - Normal Normal Negative 84.1 105 0.8 80.1 87 86 Normal 
70 Maruthu 44 12 Yes - - - - - Normal Normal Negative 89.2 112.8 0.79 79.08 83 90 Normal 
71 Abbas 60 44 Yes - - - - - Normal Normal Negative 80.7 116.2 0.69 69.45 74 75 Stage I 
72 Chinnamani 41 18 No - - - - - Normal Normal Negative 84.8 106.6 0.8 79.55 83 80 Normal 
73 David 51 32 Yes - - - - - Normal Normal Negative 84.6 106 0.8 79.81 88 86 Normal 
74 Anbarasan 35 12 No - - - - - Normal Normal Negative 87.6 115 0.76 76.17 80 82 Normal 
75 Periyasamy 46 36 Yes - - - - - Normal Normal Negative 85.9 109.9 0.78 78.16 84 89 Normal 
76 Natharshah 32 19 No - - - - - Normal Normal Negative 83.9 106 0.79 79.15 89 85 Normal 
77 Maruthanayagam 42 15 No - - - - - Normal Normal Negative 85.6 110.3 0.78 77.61 82 82 Normal 
78 Innasi 55 50 Yes - - - - - Normal Normal Negative 80.1 116.2 0.69 68.93 75 74 Stage I 
79 Pasupathy 43 32 No - - - - - Normal Normal Negative 83.1 98.4 0.84 84.45 82 83 Normal 
80 Rajkumar 58 36 No - - - - - Normal Normal Negative 87.7 116.4 0.75 75.34 89 80 Normal 
81 Marthandam 54 32 Yes - - - - - Normal Normal Negative 85.9 105.3 0.82 81.58 85 82 Normal 
82 Dharmalingam 45 22 No - - - - - Normal Normal Negative 84.3 106.7 0.79 79.01 86 84 Normal 
83 Prakash 54 27 No - - - - - Normal Normal Negative 86 104.3 0.82 82.45 80 84 Normal 
84 Nesamani 31 14 No - - - - - Normal Normal Negative 85.4 105 0.81 81.33 82 90 Normal 
85 Chandran 55 26 No - - - - - Normal Normal Negative 85.2 110.6 0.77 77.03 81 83 Normal 
86 Palavendran 58 60 Yes - - - - - Normal Normal Negative 78.9 74.2 1.06 106.3 85 86 Mixed 
87 Sekaran 58 48 No - - - - - Normal Normal Negative 81.2 118.9 0.68 68.29 72 71 Stage I 
88 Natarajan 62 20 No - - - - - Normal Normal Negative 83.9 102.5 0.82 81.85 85 86 Normal 
FEV1 Sl.No NAME AGE Pack years Cough Chest 
pain 
wheeze Dys 
pnoea 
Cre 
pitation 
rhonchai ECG X-RAY SPUTUM AFB FEV1% FVC% 
FVC 
FEV1 
FVC 
% 
FEF50 FEF25-75 TYPE 
89 Issac 43 12 No - - - - - Normal Normal Negative 83.9 99.3 0.84 84.49 88 81 Normal 
90 Thanasekaran 52 30 Yes - - - - - Normal Normal Negative 84.5 106.9 0.79 79.05 80 88 Normal 
91 Annamalai 59 52 No - - - - - Normal Normal Negative 87.7 116.6 0.75 75.21 89 82 Normal 
92 Saravanan 39 14 No - - - - - Normal Normal Negative 87.6 111 0.79 78.92 85 81 Normal 
93 Rajagopalan 42 32 Yes - - - - - Normal Normal Negative 81.6 118.4 0.69 68.92 75 74 Stage I 
94 Namasivayam 57 39 No - - - - - Normal Normal Negative 82.4 118.2 0.7 69.71 71 73 Stage I 
95 Ibrahim 34 22 Yes - - - - - Normal Normal Negative 82.9 117.3 0.71 70.67 73 74 Stage I 
96 Kamarajan 64 21 Yes - - - - - Normal Normal Negative 80.5 117.4 0.69 68.57 72 74 Stage I 
97 Thandapani 41 24 No - - - - - Normal Normal Negative 86.2 114.2 0.75 75.48 85 84 Normal 
98 Pakker Mohamed 57 48 No - - - - - Normal Normal Negative 81.3 120 0.68 67.75 73 74 Stage I 
99 Dhanapal 35 15 No - - - - - Normal Normal Negative 84.7 112 0.76 75.63 90 82 Normal 
100 Amalraj 59 44 Yes - - - - - Normal Normal Negative 82.4 118.2 0.7 69.71 71 73 Stage I 
101 Mahalingam 41 32 No - - - - - Normal Normal Negative 85 111.8 0.76 76.03 87 86 Normal 
102 Sundarraj 59 44 No - - - - - Normal Normal Negative 66.6 110.1 0.6 60.49 72 71 Stage II 
103 Fulgunan 47 28 No - - - - - Normal Normal Negative 87.5 107.5 0.81 81.4 84 83 Normal 
104 Rajendraprasad 38 22 No - - - - - Normal Normal Negative 86.2 103 0.84 83.69 83 85 Normal 
105 Senthilkumar 53 48 No - - - - - Normal Normal Negative 88 114.3 0.77 76.99 82 90 Normal 
106 Rahamadulla 50 40 No - - - - - Normal Normal Negative 81.5 116.9 0.7 69.72 75 72 Stage I 
107 Chakravarthi 59 60 No - - - - - Normal Normal Negative 80.6 118.4 0.68 68.07 74 75 Stage I 
108 Nazirudin 46 12 No - - - - - Normal Normal Negative 84.7 102.4 0.83 82.71 83 81 Normal 
109 Govindaraj 33 25 Yes - - - - - Normal Normal Negative 82.2 113.9 0.72 72.17 75 73 Stage I 
110 Sarathy 64 55 No - - - - - Normal Normal Negative 80.2 116.2 0.69 69.02 74 73 Stage I 
111 Nizam Ali 60 20 No - - - - - Normal Normal Negative 83.1 98.4 0.84 84.45 88 80 Normal 
112 Seeni Rowthar 37 11 No - - - - - Normal Normal Negative 83.9 99 0.85 84.75 90 86 Normal 
113 Arockiaraj 48 11 No - - - - - Normal Normal Negative 83.2 100.1 0.83 83.12 87 88 Normal 
114 Jeyapaul 62 36 No - - - - - Normal Normal Negative 81.7 119.4 0.68 68.43 74 75 Stage I 
115 Sethuraman 42 28 No - - - - - Normal Normal Negative 88.3 104.7 0.84 84.34 85 89 Normal 
116 Bhaskaran 65 36 No - - - - - Normal Normal Negative 83.4 100.5 0.83 82.99 82 87 Normal 
117 Karuppanan 32 16 Yes - - - - - Normal Normal Negative 84.1 106 0.79 79.34 80 87 Normal 
118 Santhakumar 63 24 No - - - - - Normal Normal Negative 84.2 108.6 0.78 77.53 81 80 Normal 
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119 Loganathan 65 25 No - - - - - Normal Normal Negative 84.6 104 0.81 81.35 84 83 Normal 
120 Rahimbai 42 24 No - - - - - Normal Normal Negative 80.3 119 0.67 67.48 74 75 Stage I 
121 Muniandi 39 24 No - - - - - Normal Normal Negative 85.7 101 0.85 84.85 84 86 Normal 
122 Jhonson 64 29 No - - - - - Normal Normal Negative 84.1 107.5 0.78 78.23 82 80 Normal 
123 Parthasarathy 62 40 Yes - - - - - Normal Normal Negative 87.6 112.8 0.78 77.66 86 88 Normal 
124 Gurusamy 51 64 No - - - - - Normal Normal Negative 86.3 112.7 0.77 76.57 84 87 Normal 
125 Chinnamani 61 60 No - - - - - Normal Normal Negative 67 108.3 0.62 61.87 71 73 Stage II 
126 Soundararajan 31 16 No - - - - - Normal Normal Negative 84.6 108 0.78 78.33 80 86 Normal 
127 Balaji 33 12 No - - - - - Normal Normal Negative 85.2 103 0.83 82.72 81 83 Normal 
128 Muraldharan 48 36 Yes - - - - - Normal Normal Negative 55.7 96.4 0.58 57.78 71 72 Stage II 
129 Panneerselvam 54 28 No - - - - - Normal Normal Negative 86.4 115.2 0.75 75 81 87 Normal 
130 Nagaraja 31 16 No - - - - - Normal Normal Negative 89.6 118.2 0.76 75.8 85 87 Normal 
131 Jegadeesan 58 30 No - - - - - Normal Normal Negative 87.6 116.6 0.75 75.13 80 80 Normal 
132 Pandiaraj 53 24 Yes - - - - - Normal Normal Negative 85.6 114 0.75 75.09 81 86 Normal 
133 Rajappan 64 28 No - - - - - Normal Normal Negative 80.7 118 0.68 68.39 75 74 Stage I 
134 Kunjappan 51 24 No - - - - - Normal Normal Negative 85.4 100.8 0.85 84.72 85 88 Normal 
135 Vadivel 57 30 No - - - - - Normal Normal Negative 88.1 114.4 0.77 77.01 88 80 Normal 
136 Jacob 65 50 No - - - - - Normal Normal Negative 79 72.4 1.09 109.1 89 91 Mixed 
137 Balu 55 24 No - - - - - Normal Normal Negative 88.2 114.3 0.77 77.17 83 89 Normal 
138 Ravindran 61 21 No - - - - - Normal Normal Negative 83.4 104.9 0.8 79.5 86 85 Normal 
139 Sangu Goundar 37 12 Yes - - - - - Normal Normal Negative 84.9 111 0.76 76.49 85 81 Stage I 
140 Thanikachalam 63 28 No - - - - - Normal Normal Negative 86.7 114 0.76 76.05 86 89 Normal 
141 Cherian 59 33 No - - - - - Normal Normal Negative 53.5 94.8 0.56 56.43 73 72 Stage II 
142 Anandan 31 24 No - - - - - Normal Normal Negative 85.4 117 0.73 72.99 84 90 Normal 
143 Veerabahu 64 42 No - - - - - Normal Normal Negative 87.4 112 0.78 78.04 87 88 Normal 
144 Duraisamy 52 30 No - - - - - Normal Normal Negative 84.7 109.4 0.77 77.42 80 82 Normal 
145 Rajangam 40 18 Yes - - - - - Normal Normal Negative 83 109 0.76 76.15 84 85 Normal 
146 Sudalaiandi 65 48 Yes - - - - - Normal Normal Negative 81.1 119.5 0.68 67.87 73 72 Stage I 
147 Thiagarajan 48 30 No - - - - - Normal Normal Negative 80.1 119.7 0.67 66.92 74 73 Stage I 
148 Vincent 65 33 No - - - - - Normal Normal Negative 85.6 110.3 0.78 77.61 82 82 Normal 
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149 Kumaraguru 58 20 Yes - - - - - Normal Normal Negative 86.4 110 0.79 78.55 81 87 Normal 
150 Bangaru 32 20 No - - - - - Normal Normal Negative 85.1 106 0.8 80.28 86 83 Normal 
151 Rajendran 45 Nil No - - - - - Normal Normal Negative 84.2 115.2 0.84 
84.3
4 83 83 Normal 
152 Vellaisamy 38 Nil No - - - - - Normal Normal Negative 85.6 110.5 0.77 
77.4
7 81 90 Normal 
153 Subburajan 72 Nil No - - - - - Normal Normal Negative 86.8 113.7 0.76 
76.3
4 87 89 Normal 
154 Mookkandi 57 Nil No - - - - - Normal Normal Negative 80.9 120 0.67 
67.4
2 70 71 Normal 
155 Nallusamy 64 Nil Yes - - - - - Normal Normal Negative 89.1 109.9 0.81 
81.0
7 87 86 Normal 
156 James 70 Nil No - - - - - Normal Normal Negative 83.4 109 0.77 
76.5
1 85 82 Normal 
157 Fakrudheen 43 Nil No - - - - - Normal Normal Negative 84.1 109.6 0.77 
76.7
3 85 84 Normal 
158 Palavesakonar 39 Nil No - - - - - Normal Normal Negative 86.7 111 0.78 
78.1
1 83 84 Normal 
159 Babulal 54 Nil No - - - - - Normal Normal Negative 81.5 119.2 0.68 
68.3
7 73 72 Normal 
160 Rangegoundar 67 Nil No - - - - - Normal Normal Negative 77 74.3 1.04 
103.
63 84 82 Normal 
161 Arockiam 59 Nil No - - - - - Normal Normal Negative 89 106.4 0.84 
83.6
5 80 84 Normal 
162 Thangadurai 48 Nil No - - - - - Normal Normal Negative 80.9 118.3 0.68 
68.3
9 75 74 Normal 
163 Sridharan 64 Nil No - - - - - Normal Normal Negative 78.4 72.6 1.08 
107.
99 82 81 Normal 
164 Rangannan 71 Nil No - - - - - Normal Normal Negative 83.7 99.9 0.84 
83.7
8 88 85 Normal 
165 Krishnan 52 Nil No - - - - - Normal Normal Negative 80.5 118.6 0.68 
67.8
8 71 70 Normal 
166 Rajarathinam 61 Nil No - - - - - Normal Normal Negative 84.8 105.5 0.80 
80.3
8 87 85 Normal 
167 Chokkanathan 48 Nil Yes - - - - - Normal Normal Negative 85.6 108 0.79 79.2 86 81 Normal 
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168 Williams 57 Nil No - - - - - Normal Normal Negative 81.7 118.8 0.69 
68.7
7 73 73 Normal 
169 Dhandapani 60 Nil No - - - - - Normal Normal Negative 84.9 105.3 0.81 
80.6
3 86 87 Normal 
170 Karuppan 45 Nil No - - - - - Normal Normal Negative 52.4 92.4 0.57 
56.7
1 71 73 Normal 
171 Robert 74 Nil No - - - - - Normal Normal Negative 84.8 106.6 0.80 
79.5
5 83 80 Normal 
172 Ismail 47 Nil No - - - - - Normal Normal Negative 84.9 109.4 0.78 
77.6
1 83 87 Stage I 
173 Raju 72 Nil Yes - - - - - Normal Normal Negative 83 98 0.85 
84.6
9 81 87 Normal 
174 Malleswaran 53 Nil No - - - - - Normal Normal Negative 80.2 119.2 0.67 
67.2
8 73 74 Normal 
175 Surianarayanan 68 Nil No - - - - - Normal Normal Negative 82.1 120 0.68 
68.4
2 73 72 Normal 
176 Venkatraj 52 Nil Yes - - - - - Normal Normal Negative 85.2 107.8 0.79 
79.0
4 82 84 Normal 
177 Manickam 48 Nil No - - - - - Normal Normal Negative 81.9 119.4 0.69 
68.5
9 75 74 Normal 
178 Prakasam 56 Nil No - - - - - Normal Normal Negative 83.9 99.9 0.84 
83.9
8 85 81 Normal 
179 Thirumal 60 Nil No - - - - - Normal Normal Negative 85.4 111.3 0.77 
76.7
3 81 81 Normal 
180 Subbanna 55 Nil No - - - - - Normal Normal Negative 88.4 108 0.82 
81.8
5 86 83 Normal 
181 Babuji 42 Nil No - - - - - Normal Normal Negative 85.1 111.6 0.76 
76.2
5 90 84 Normal 
182 Velu 37 Nil No - - - - - Normal Normal Negative 83.4 100.5 0.83 
82.9
9 82 87 Normal 
183 Duraiappan 42 Nil No - - - - - Normal Normal Negative 76.3 70.5 1.08 
108.
23 84 88 Normal 
184 Jeevanandham 35 Nil No - - - - - Normal Normal Negative 85.9 109.6 0.78 
78.3
8 83 80 Normal 
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185 Madhavan 59 Nil No - - - - - Normal Normal Negative 85.3 110.5 0.77 
77.1
9 90 85 Normal 
186 Chandrasekaran 69 Nil No - - - - - Normal Normal Negative 84.8 106.6 0.80 
79.5
5 83 80 Normal 
187 Varadarajan 67 Nil No - - - - - Normal Normal Negative 81.5 116.9 0.70 
69.7
2 75 72 Normal 
188 Joel 42 Nil No - - - - - Normal Normal Negative 64.3 109.5 0.59 
58.7
2 71 72 Normal 
189 Mohemmad 38 Nil No - - - - - Normal Normal Negative 84.7 107.4 0.79 
78.8
6 88 82 Normal 
190 Punniakodi 51 Nil No - - - - - Normal Normal Negative 77.3 72.9 1.06 
106.
04 84 87 Normal 
191 Sitaraman 46 Nil No - - - - - Normal Normal Negative 83.6 101.5 0.82 
82.3
6 88 83 Normal 
192 Ilango 62 Nil No - - - - - Normal Normal Negative 75.9 73.4 1.03 
103.
41 88 87 Normal 
193 Dharmarajan 39 Nil No - - - - - Normal Normal Negative 83.2 99.9 0.83 
83.2
8 88 89 Normal 
194 Packianathan 44 Nil No - - - - - Normal Normal Negative 80.7 116.2 0.69 
69.4
5 74 75 Normal 
195 Arunagiri 57 Nil No - - - - - Normal Normal Negative 88.1 114.4 0.77 
77.0
1 88 80 Normal 
196 Paranjothy 53 Nil No - - - - - Normal Normal Negative 86.5 115.3 0.75 
75.0
2 82 85 Normal 
197 Innasi Goundar 48 Nil Yes - - - - - Normal Normal Negative 86.3 112.7 0.77 
76.5
7 84 87 Normal 
198 Deenadayalan 37 Nil No - - - - - Normal Normal Negative 84.3 105.2 0.80 
80.1
3 87 85 Normal 
199 Venkoban 54 Nil No - - - - - Normal Normal Negative 87.1 118.2 0.74 
73.6
9 84 90 Normal 
200 Francis 61 Nil No - - - - - Normal Normal Negative 81.4 119.3 0.68 
68.2
3 75 75 Normal 
 
 
